The prevalence of cardiac and renal failure has been rising rapidly over the last decade. Despite this, there are no effective treatments for cardiac or renal failure. The concomitant existence of both cardiac and renal disease is termed the cardiorenal syndrome. The primary interest in my laboratory is to investigate the mechanisms underlying the pathogenesis of cardiorenal syndrome and to develop novel treatments for this disease state. To this end, our recent data indicate that reduced nitric oxide bioavailability and resulting inflammation contribute to the development of renal disease in heart failure. Accordingly, we are currently investigating novel therapeutic approaches which can restore nitric oxide bioavailability in cardiorenal syndrome.